These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12951812)

  • 1. The role of flavin-containing monooxygenases in drug metabolism and development.
    Cashman JR
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):486-93. PubMed ID: 12951812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development.
    Koukouritaki SB; Hines RN
    Pharmacogenomics; 2005 Dec; 6(8):807-22. PubMed ID: 16296944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in retrometabolic drug design and targeting approaches.
    Bodor N
    Pharmazie; 2000 Mar; 55(3):163-6. PubMed ID: 10756533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guiding molecules towards drug-likeness.
    Egan WJ; Walters WP; Murcko MA
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):540-9. PubMed ID: 12197312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New horizons in drug metabolism, pharmacokinetics and drug discovery.
    Palmer AM
    Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of experimental diabetes on hepatic drug metabolism in rats: the activities of flavin-containing monooxygenase, the phase II conjugation reactions and glutathione related enzymes.
    Toda A; Eyanagi R; Saito H; Soeda S; Shimeno H; Moriyama M; Shigematsu H
    Res Commun Mol Pathol Pharmacol; 2005; 117-118():13-27. PubMed ID: 18426076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human hepatocytes: isolation, cryopreservation and applications in drug development.
    Li AP
    Chem Biol Interact; 2007 May; 168(1):16-29. PubMed ID: 17270162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of pharmaceutical profiling assays for optimization of drug-like properties.
    Di L; Kerns EH
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development.
    Cashman JR
    Drug Discov Today; 2004 Jul; 9(13):574-81. PubMed ID: 15203093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavin-containing monooxygenases: mutations, disease and drug response.
    Phillips IR; Shephard EA
    Trends Pharmacol Sci; 2008 Jun; 29(6):294-301. PubMed ID: 18423897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biochemistry of drug metabolism--an introduction: part 5. Metabolism and bioactivity.
    Testa B; Krämer SD
    Chem Biodivers; 2009 May; 6(5):591-684. PubMed ID: 19479846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.